VELTASSA
Peakpatiromer
NDAORALPOWDER
Approved
Oct 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
VELTASSA (patiromer) is potassium ion binding activity [moa]. First approved in 2015.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELTASSA (patiromer) is an oral potassium binder indicated for hyperkalemia management in patients with chronic kidney disease, heart failure, or diabetes. It works by binding potassium in the gastrointestinal tract, reducing serum potassium levels. The drug is administered as an oral powder and represents a non-absorbed, selective potassium-binding mechanism.
$154MPart D
PeakStable
7.3 years to LOEProduct remains at peak revenue with 141K+ annual claims, suggesting stable commercial operations and a mature brand team focused on market maintenance.
Mechanism of Action
Potassium Ion Binding Activity
Pharmacologic Class:
Potassium Binder
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
Started Apr 2019
1,195 enrolled
Hyperkalemia
Evaluation of Patiromer in Heart Failure Patients
Started Apr 2009
120 enrolled
HyperkalemiaHeart Failure
Why This Matters for Your Career
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.